ESOC 2026 | New insights into cerebral amyloid angiopathy from the SENECA registry
Benedetta Storti, MD, University of Milano-Bicocca, Milan, Italy, discusses the preliminary results of the SENECA registry (NCT04204642), an Italian multicenter cohort study and patient registry of patients with cerebral amyloid angiopathy aimed at better defining the disease natural history and identifying clinical and neuroradiological markers of disease progression. The study has shown how the pathology can present with a wider range of symptoms than traditionally expected, suggesting that the current diagnostic criteria may require updating to improve sensitivity and specificity. This interview took place at the 12th European Stroke Organisation Conference (ESOC) in Maastricht, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s a super great pleasure to be here at the European Stroke Organization Congress, because finally we can present the preliminary results of the SENECA Registry, which is a nationwide Italian registry of patients affected by cerebral amyloid angiopathy, which is a pathology that increases the risk of spontaneous cerebral hemorrhage. It’s a very severe pathology and the prevalence of this illness is increasing because of the aging of the population...
It’s a super great pleasure to be here at the European Stroke Organization Congress, because finally we can present the preliminary results of the SENECA Registry, which is a nationwide Italian registry of patients affected by cerebral amyloid angiopathy, which is a pathology that increases the risk of spontaneous cerebral hemorrhage. It’s a very severe pathology and the prevalence of this illness is increasing because of the aging of the population. The study, the registry, it’s quite interesting because we have collected data from 577 patients, which is a super large number of patients. Traditionally, this pathology was described just in smaller cohorts or very, I would say, selected cohorts of patients affected by brain hemorrhage. We have discovered, for the sake of time, I’m going to be very brief, that the pathology can present with many more symptoms than traditionally expected and traditionally accepted. We got optimal diagnostic criteria, the Boston criteria, which are optimal if you’re speaking about a patient with hemorrhagic symptoms, but are sub-optimal as far as sensitivity and specificity if you have a patient that presents with cognitive impairment or something else. So, to your question, the things that we have discovered is the fact that we really need to update the diagnostic criteria to be a little bit more flexible maybe in the diagnosis without losing specificity and maybe the usage of biomarkers, the fluid biomarkers, could be helpful to improve the diagnostic criteria.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
